Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06735833 · ClinicalTrials.gov registry record · NA

MMA Embolization for Refractory Chronic Migraine

A NA study of Migraine, sponsored by Cerenovus, Part of DePuy Synthes Products.

Recruiting
Registry status
NA
Development phase
70
Enrollment target
7
Study locations

NCT06735833 is a NA study of Migraine that is actively recruiting participants, run by Cerenovus, Part of DePuy Synthes Products. The registered enrollment target is 70 participants, below the 358-participant average among 102 other Migraine trials with a reported enrollment target (80% lower). The trial reports 7 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06735833, a NA study of Migraine, is actively recruiting participants, sponsored by Cerenovus, Part of DePuy Synthes Products.

RECRUITING
Registry status
NA
Development phase
70 participants
Enrollment target
7
Study locations

Study Summary

This is a prospective, multi-center, feasibility study to investigate safety and effectiveness of TRUFILL n-BCA liquid embolic system in bilateral middle meningeal artery (MMA) embolization for the treatment of refractory chronic migraine.

Conditions Studied

Migraine

Interventions

  • DEVICE Middle Meningeal Artery embolization

Study Locations (7)

New York

  • University of Buffalo Medical Center - Buffalo
  • Mount Sinai - New York
  • Stony Brook University Medical Center - Stony Brook

Connecticut

  • Hartford Hospital - Hartford

Pennsylvania

  • Thomas Jefferson University Hospital - Philadelphia

Tennessee

  • Semmes Murphey Foundation - Memphis

West Virginia

  • West Virginia University - Morgantown

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2025-04-23
Est. Completion 2029-05-15
Phase NA

Sponsor

Cerenovus, Part of DePuy Synthes Products

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06735833

The ClinicalTrials.gov registry entry for NCT06735833 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 358-participant average among 102 other Migraine trials with a reported enrollment target (80% lower). The listed sponsor is Cerenovus, Part of DePuy Synthes Products, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 1 intervention - of which Middle Meningeal Artery embolization is the first listed.

NCT06735833 reports 7 study locations spanning 5 distinct geographic areas - top geographies include New York, Connecticut, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT06735833 about?

NCT06735833 is a clinical study titled "MMA Embolization for Refractory Chronic Migraine". This is a prospective, multi-center, feasibility study to investigate safety and effectiveness of TRUFILL n-BCA liquid embolic system in bilateral middle meningeal artery (MMA) embolization for the treatment of refractory chronic migraine.

What is the current status of trial NCT06735833?

This trial is currently recruiting. It is a NA study. The enrollment target is 70 participants. The study started on 2025-04-23. Estimated completion is 2029-05-15.

What conditions does trial NCT06735833 study?

This clinical trial studies the following conditions: Migraine.

What interventions are being tested in trial NCT06735833?

The interventions under investigation include: Middle Meningeal Artery embolization (DEVICE).

Who is sponsoring clinical trial NCT06735833?

This trial is sponsored by Cerenovus, Part of DePuy Synthes Products, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06735833 being conducted?

This trial has 7 study locations across Connecticut, New York, Pennsylvania, Tennessee, West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Migraine

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Migraine

All registered trials for this condition

Connecticut

All trials with a study site in Connecticut

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.